- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01689467
Efficacy and Safety of Fermented Velvet Antler Extract on Fatigue Recovery After Exercise
August 21, 2019 updated by: Soo-Wan Chae, Chonbuk National University Hospital
The investigators performed a 12-week, randomized, double-blind, placebo-controlled human trial to evaluate the efficacy and safety of Fermented Velvet Antler extract on fatigue recovery after exercise.
The investigators measured fatigue recovery parameters , including lactate, ammonia, inorganic phosphorus, creatine kinase and LDH, and monitored their blood pressure.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
60
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Jeollabuk-do
-
Jeonju, Jeollabuk-do, Korea, Republic of, 560-822
- Clinical Trial Center for Functional Foods; Chonbuk National University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years to 60 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Males and females 19-60 years old
- Hemoglobin concentration between 13 and 14 g/dL(men), 12 and 13 g/dL(women)
- Able to give informed consent
Exclusion Criteria:
- Allergic or hypersensitive to any of the ingredients in the test products
- History of reaction to any of the test products or of gastrointestinal diseases such as Crohn's disease or gastrointestinal surgery
- Participation in any other clinical trials within past 2 months
- Laboratory test, medical or psychological conditions deemed by the investigators to interfere with successful participation in the study
- Pregnant or lactating women etc.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Placebo (1g/day)
|
Experimental: Fermented Velvet Antler extract
|
Fermented Velvet Antler extract (1g/day)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in lactate
Time Frame: 12 weeks
|
Lactate was measured in study visit 1(0 week) and visit 3(12 week).
|
12 weeks
|
Changes in ammonia
Time Frame: 12 weeks
|
Ammonia was measured in study visit 1(0 week) and visit 3(12 week).
|
12 weeks
|
Changes in inorganic phosphorus
Time Frame: 12 weeks
|
Inorganic phosphorus was measured in study visit 1(0 week) and visit 3(12 week).
|
12 weeks
|
Changes in creatine kinase
Time Frame: 12 weeks
|
Creatine kinase was measured in study visit 1(0 week) and visit 3(12 week).
|
12 weeks
|
Changes in Lactage dehydrogenase(LDH)
Time Frame: 12 weeks
|
Lactage dehydrogenase(LDH) was measured in study visit 1(0 week) and visit 3(12 week).
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in Multidimensional Fatigue Scale(MFS)
Time Frame: 12 weeks
|
Multidimensional Fatigue Scale(MFS) was measured in study visit 1(0 week) and visit 3(12 week).
|
12 weeks
|
Changes in 36-Item Short-Form Health Survey(SF-36)
Time Frame: 12 weeks
|
36-Item Short-Form Health Survey(SF-36) was measured in study visit 1(0 week) and visit 3(12 week).
|
12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 25, 2013
Primary Completion (Actual)
June 26, 2014
Study Completion (Actual)
June 26, 2014
Study Registration Dates
First Submitted
September 18, 2012
First Submitted That Met QC Criteria
September 18, 2012
First Posted (Estimate)
September 21, 2012
Study Record Updates
Last Update Posted (Actual)
August 26, 2019
Last Update Submitted That Met QC Criteria
August 21, 2019
Last Verified
August 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KD-FR-FVE
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Fatigue Syndrome
-
Oslo University HospitalCompletedAdolescent Chronic Fatigue SyndromeNorway
-
Shanghai University of Traditional Chinese MedicineShanghai Yueyang Integrated Medicine HospitalRecruiting
-
AIM ImmunoTech Inc.Available
-
Ho Cheol Shin, M.D., Ph.D.Green Cross Corporation; Ajou University School of Medicine; SymyooCompletedChronic Fatigue Syndrome | Idiopathic Chronic FatigueKorea, Republic of
-
King Saud UniversityCompletedChronic Fatigue Syndrome (CFS)
-
Stony Brook UniversityCompletedChronic Fatigue Syndrome | Medically Unexplained Chronic FatigueUnited States
-
Centre Hospitalier Universitaire de Saint EtienneNot yet recruitingChronic Fatigue SyndromeFrance
-
Power Life Sciences Inc.Not yet recruitingChronic Fatigue SyndromeUnited States
-
Heilongjiang Quanle Pharmaceutical Co., Ltd.Not yet recruiting
-
King's College LondonSouth London and Maudsley NHS Foundation TrustNot yet recruiting
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States